MUM1/IRF4 IHC (Myélome multiple oncogène 1)
Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.
| ID | BIO-MUM1-IHC |
|---|---|
| Type | Biomarqueur |
| Alias | IRF4 IHCFacteur de réglementation de l'interféron 4MUM1 immunohistochimieMUM1/IRF4 expression de protéines |
| État | reviewed 2026-05-05 | pending_clinical_signoff |
| Maladies | Aucune déclaration |
| Sources | SRC-NCCN-BCELL-2025 |
Données biomarqueurs
| Type de biomarqueur | protein_expression_ihc |
|---|---|
| Détails de la mutation | {"gene_id_ncbi": 3662, "gene_symbol": "IRF4", "note": "IRF4/MUM1 is a transcription factor expressed in post-germinal center B-cells, plasma cells, T-cells (activated), and NK-cells. In DLBCL: MUM1 positivity (>30% of tumor cells) in the Hans algorithm Step 3 context indicates non-GCB/ABC subtype. Nuclear staining pattern.\n"} |
| Mesure | MéthodeIHC on FFPE biopsy. Anti-MUM1/IRF4 antibody (clone MUM1p). Nuclear staining. Cut-off: >30% positive tumor cell nuclei = MUM1 positive. Hans algorithm Step 3: when CD10 negative AND BCL6 positive — MUM1 determines final COO: MUM1 >30% → non-GCB; MUM1 ≤30% → GCB. |
| Biomarqueurs connexes | BIO-CD10-IHC BIO-BCL6-IHC BIO-DLBCL-COO-HANS BIO-CD30-IHC |
Notes
MUM1/IRF4 IHC completes the Hans algorithm for DLBCL COO classification. The Hans algorithm has ~80% concordance with GEP (Lymph2Cx) for GCB/non-GCB classification. Non-GCB DLBCL (by Hans) has historically worse prognosis with R-CHOP and is the target of emerging combination therapies (e.g., lenalidomide + R-CHOP = R²-CHOP in the Phoenix trial — showed benefit in young/fit non-GCB, particularly non-GCB by COO). The Hans IHC panel (CD10, BCL6, MUM1) is recommended in all DLBCL where molecular COO profiling is not available.
Utilisé par
Biomarqueur
BIO-BCL6-IHC- BCL6 IHC (expression protéique)BIO-CD10-IHC- CD10 IHC (CALLA, néprilysine)